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CD4 T and regulatory T cells (Tregs) seem to play a key role in persistence of hepatitis B
virus (HBV) infection.However, themolecular events by which Tregs exert theirmodulatory
activity are largely unknown. The transcriptional profiles of CD4 T cells of healthy con-
trols (HCs) and patients affected by acute hepatitis B (AVH-B) or chronic hepatitis B (CHB)
infection were established using a custom expression array consisting of 350 genes relevant
for CD4 T cell and Treg function. These studies were complemented by real-time reverse-
transcription polymerase chain reaction. Peripheral bloodmononuclear cells (PBMCs) were
also analyzed for the presence of Tregs, which were more abundant in the acute stage of the
disease (7%) than inHCs and CHB infection (HCs versus AVH-B,P 0.003; AVH-B versus
CHB, P  0.04). One hundred eighteen genes (34%) intrinsically differentiate HBV-in-
fected patients from HCs. Using gene ontology, we identified T cell receptor signaling and
clusterization, mitogen-activated protein kinase kinase signaling, cell adhesion, cytokines
and inflammatory responses, cell cycle/cell proliferation, and apoptosis as the most promi-
nent affected modules. A higher expression of CCR1, CCR3, CCR4, CCR5, and CCR8 was
seen in AVH-B than in CHB-infected patients and HCs. Annotation of the interconnected
functional network of genes provided a unique representation of global immune activation
during acute infection. Almost all genes were down-regulated in patients with CHB infec-
tion. Conclusion: The fingerprints enable clear discrimination between patients suffering
from AVH-B or CHB infection. The observed profiles suggest accumulation of effector T
cells with a potential role in necro-inflammation during the acute stage. Subsequent down-
regulated effector functions support the hypothesis of suppressed CD4 effector T cells
favoring viral persistence in the chronic infection stage. (HEPATOLOGY 2009;49:781-790.)
Hepatitis B virus (HBV) infection is one of themajor infectious diseases; more than 360 mil-lion people worldwide have chronic hepatitis B
(CHB) infection. Acute hepatitis B (AVH-B) infection
does not get cleared by the host immune system in about 5%
of adult patients, leading to the development of CHB.1
HBV infection is a dynamic process, and the outcome
of infection varies due to differences in host response.
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HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HC, healthy control; IFN, interferon; Ig, immunoglobulin; IL, interleukin;
MAPKK, mitogen-activated protein kinase kinase; NF-B, nuclear factor B; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse-transcription polymerase chain
reaction; TCR, T cell receptor; TNF, tumor necrosis factor; Treg, regulatory T cell.
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Some subjects with CHB remain asymptomatic, even af-
ter many decades of infection, with slow disease progres-
sion, whereas others rapidly progress to cirrhosis and
hepatocellular carcinoma. A strong genetic component
withmodified gene expression seems to be amajor driving
force affecting the course of viral hepatitis.2-5
Development of persistent infection following AVH-B
is associated with T cell hyporesponsiveness and dysfunc-
tion.6 Recently, the role of CD4CD25 regulatory T
cells (Tregs) has been shown in persistent viral infec-
tions.7-11 The virus-dependent induction of Tregs may
have two different outcomes depending on the specific
balance. On the one hand, it may be an important process
to limit excessive immunopathological damage during vi-
ral clearance. On the other hand, it could also facilitate
viral persistence by down-modulating critical effector
cells.12,13 Depletion of CD4CD25 T cells in herpes
simplex virus–infected mice resulted in enhanced virus-
specific CD8 T cell activity in the acute phase of infec-
tion, as well as after viral clearance. Insufficient CD8
effector cell response was also observed in chronic infec-
tion with the Friends virus, as a result of Treg accumula-
tion at the site of infection.14,15
Recent studies of HBV confirm the important role of
Tregs in the outcome of viral infection. A broad analysis
of the frequency and function of CD4CD25Tregs in
the blood with AVH-B, CHB, severe CHB, and HCs
revealed that patients with severe CHB infection showed
significantly higher number of Tregs compared with pa-
tients with mild CHB and early AVH-B infection, and
that CD4CD25Foxp3 T cells accumulate in the
livers of patients with severe CHB infection. In convales-
cent AVH-B patients, the number of circulating Tregs
was increased to normal levels after viral clearance.8,11
These data suggest that Tregs play a pivotal role in the
modulation of T cell responses against HBV during in-
fection, thereby influencing the outcome of the disease.
Although, some progress has been made in the charac-
terization of AVH-B and CHB at the cellular level, there
is a paucity of knowledge about the underlying molecular
mechanisms and specific genes affected during host re-
sponse against HBV. Thus, we performed a comparative
evaluation of CD4 T cells purified from peripheral
blood of patients with AVH-B and CHB infection in
comparison to HCs. To gain insight on how the status of
infection influences the overall expression pattern of
CD4 T cells, we analyzed their transcriptional profiles
using microarray technology. We used a focused gene
array consisting of 350 CD4 T cell–specific genes, cus-
tomized to investigate Treg-associated genes.16
Patients and Methods
Patients and Samples. Three groups of subjects were
included in the present study (Table 1). The first group
comprised 19 patients with AVH-B diagnosed by clinical
symptoms of acute hepatitis and serum alanine amino-
transferase levels 10 times the upper limit of normal
with no past history and clinical, biochemical, or radio-
logical evidence of chronic liver disease. These patients
were hepatitis B surface antigen (HBsAg)-positive, hepa-
titis B e antigen (HBeAg)-positive, anti-HBeAg–negative,
immunoglobulin (Ig) M anti-hepatitis B core antigen
(HBcAg)-positive and anti-HBsAg–negative. The second
group comprised 21 HBsAg-positive CHB patients for
6 months, HBeAg positive, with elevated alanine ami-
notransferase levels (1.5 times the upper limit of nor-
mal) and histological evidence of chronic hepatitis. The
third group comprised 12 HCs with no previous history
or current evidence of any liver disease, normal amino-
transferase levels, normal liver on ultrasound, and nega-
tive for HBsAg, anti-HBeAg, IgG anti-HBcAg, anti-
HCV, IgM anti–hepatitis E virus, IgM anti–hepatitis A
virus, and anti–human immunodeficiency virus. All HCs
had received vaccination for HBV in the past, had anti-
HBsAg titers 300 IU/mL, and were negative for total
antiHBc.
Exclusion criteria were regular alcohol consumption
(40 g/day for the past 5 years), diabetes, severe systemic
illness, pregnancy, hepatocellular carcinoma, coinfection
Table 1. Clinical and Virological Characteristics of the Subjects Enrolled in the Study
Parameters AVH-B (n  19) CHB (n  21) HC (n  12)
P Value*
AVH-B Versus HC CHB Versus HC
Age (years), mean  SD 29.42 14 29.4 11 29 5 NS NS
Sex (M:F) 13:6 18:3 9:3 NS NS
Serum bilirubin (mg/mL), median (range) 10.5 (0.5–33.6) 0.7 (0.2–23.8) 0.3 (0.1–0.7) P0.026 NS
Albumin (g/dL), median (range) 3.95 (2.2–4.8) 4.1 (2.7–4.8) 4 (3.5–4.2) NS NS
AST (IU/L), median (range) 605 (52–2,498) 66 (36–551) 33 (30–35) P 0.02 P0.015
ALT (IU/L), median (range) 1,170 (470–4,329) 121 (55–204) 30 (30–34) P 0.02 P0.000
Abbreviations: F, female; M, male; NS, not significant; SD, standard deviation.
*The P value was calculated for both AVH-B patients versus HCs and CHB patients versus HCs.
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with human immunodeficiency virus or other hepatitis
viruses, or immunosuppressive therapy for other associ-
ated illness. After institutional ethical committee approval,
informed consent was obtained in all cases before enrolling
the patients for conducting the various blood tests.
HBsAg, HBeAg, anti-HBeAg, IgM anti-HBcAg, IgG
anti-HBcAg, anti-HBsAg, IgM anti–hepatitis A virus,
IgM anti–hepatitis D virus, IgM anti–hepatitis E virus,
anti–human immunodeficiency virus, and anti-HCV
were detected using commercial enzyme-linked immu-
nosorbent assay kits (M/s Ranbaxy Diagnostics, India).
Twenty-milliliter blood samples were collected from
patients with acute HBV at the first presentation, with a
mean duration of 33.5  13.1 days after the onset of
jaundice. In the other groups, routine fasting blood sam-
ples were collected. After isolation of peripheral blood
mononuclear cells (PBMCs), CD4 T cells were iso-
lated. For microarray experiments, equal numbers of
CD4 T cells (100,000 cells) from each patient were
pooled and total RNA was isolated for further experi-
ments. For quantitative reverse-transcription polymerase
chain reaction (RT-PCR), individual CD4 T cells were
isolated and total RNA was purified. A minimum of 1 to
2 g of total RNA was used to make complementary
DNA for RT-PCR.
Isolation of CD4 T Cells from PBMCs and Flow
Cytometric Analysis. PBMCs were separated by Ficoll-
hypaque density gradient centrifugation. CD4 T cells
were isolated using an indirect magnetic labeling method
(Miltenyi Biotec, Germany) and were checked for purity
after staining with anti-CD4 fluorescein isothiocyanate
and PeCy7–anti-CD3 or APC–anti-CD4 and fluorescein
isothiocyanate–anti-CD25 anitbodies (BD Pharmingen).
Permeabilized cells were fixed using Cytofix/Cytoperm
(BD Pharmingen) and subsequently stained with phyco-
erythrin–anti-FoxP3 (eBiosciences). Cells were acquired
for flow cytometric analysis using FACSCalibur, and the
results were analyzed using Flow-Jo software.
Microarray Analysis. To normalize results within
each individual group, total RNA was extracted from
pooled CD4T cells (n 5 per group) using theQiagen
RNA extraction easy kit. The quality and integrity of the
total RNA isolated from CD4 T cells pools were con-
trolled by running the samples on an Agilent Technolo-
gies 2100 Bioanalyzer (Agilent Technologies, Waldbronn,
Germany). For microarray analysis, we used the human
Treg Chip as described elsewhere.16
Quantitative RT-PCR was performed in triplicate in a
7900 ABI Prism Sequence Detection system using the
Syber Green kit and specific primers (Table 2) for NCF4,
MCM5, NFKB, CCR1, CCR3, and CCR5 with Primer
Express 1.5 software (Applied Biosystems). Amplification
of -actin was used as the control for normalization. Rel-
ative quantification of each gene was analyzed by calcu-
lating the Log RQ of each sample Ct value.
Statistical Analysis. Signal intensities were qualified
and quantified using the Imagene software 5.0 (BioDis-
covery, El Segundo, CA) and normalized according to the
housekeeping controls. Genes whose signal intensities did
not exceed background levels (signal intensity was less
than background intensity plus two times standard devi-
ation) were excluded from further analysis. Significant
differentially regulated genes between AVH-B patients,
CHB patients, and HCs were identified via analysis of
variance (ANOVA) at a 95% confidence level. Multiple
testing errors were taken into account and corrected using
the Benjamini-Hochberg algorithm.17 For data visualiza-
tion in two-dimensional hierarchic clusters, the Genesis
software v1.4.0 was applied.18 Genes were annotated for
gene ontology (GO) terms using the Source annotation
tool19 and linked to external signaling maps by Gen-
Mapp.20,21 The statistical significance of intergroup dif-
ferences for continuous variables was evaluated by means
of Mann-Whitney U tests and for categorical variables
with chi-square tests. A P value  0.05 was considered
significant.
Results
Frequency Analysis of Circulating CD4CD25
Foxp3 Tregs. We analyzed peripheral blood from 19
AVH-B patients, 21 CHB patients, and 12 HCs to deter-
mine the percentage of CD4 T cells and
CD4CD25Foxp3 Tregs. The clinical characteris-
tics of the patients and the HCs enrolled in this study are
shown in Table 1. The frequency of CD4 cells was
similar in all the three groups (AVH-B, 29%; CHB, 34%;
HC, 30%) (Fig. 1A). The frequencies of Tregs in HCs
and in chronic infection were 2.18% and 3.96%, respec-
Table 2. Primer Sequences Used in Real-Time RT-PCR
Gene Primers
NCF4 5-TGAACAGCTTCCGGATGATG-3
5-TGAAGCCTCTCTTCTCCTCGAT-3
MCM5 5-ACCCTGGGACAGCCAAGTC-3
5-CTGCCTTTCCCAGACGTGTATAC-3
NFKB 5-TGATCACCAACCAGCCAGAA-3
5-TCTCGGAGCTCAGGATCACA-3
CCR1 5-ACACAGGCTTGTACAGCGAGATC-3
5-AAACACGGCGTGGACGAT-3
CCR3 5-TGCTACACAGGAATCATCAAAACG-3
5-GAGCCGGATGGCCTTGTA-3
CCR5 5-GAATATGAACGGTGAGCATTGTG-3
5-ACAACTTAAGAGCAAAAGGAAAGACAT-3
-Actin 5-CCAGCTCACCATGGATGATG-3
5-ATGCCGGAGCCGTTGTC-3
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tively, whereas in AVH-B patients it was 7% (HC versus
AVH-B, P 0.003; AVH-B versus CHB, P 0.04) (Fig.
1B).
Functional Dissection of Expression Signatures in
AVH-B and CHB Patients. CD4T cells were isolated
from peripheral blood (92% to 96% purity) for RNA
extraction. Equicellular donor pools derived from ran-
domly selected (n  5) AVH-B, CHB, or HC donors
were created to minimize overestimation of individual
expression signatures. To minimize systemic errors based
on variances during RNA processing steps and hybridiza-
tion, we performed four (three for AVH-B) individual
measures per donor pool. A unique set of 350 genes
known to be crucial for Treg and CD4 effector T cell
function was used to establish an expression profile of
CD4 cells. Significant expression levels could be de-
tected for 316 genes. A summary of this expression data is
provided in Supplementary Table 1. Principal compo-
nent analysis was used to evaluate the overall variances
between andwithin the three groups. A clear separation of
the three CD4 pools was achieved by the principal com-
ponent analysis (Fig. 2). In HCs, a higher intragroup
variance was observed in comparison to the other groups.
Using ANOVA and the Benjamini-Hochberg FDR algo-
rithm at a confidence level of 95% (corrected P value 
0.05), we demonstrated that 118 out of 316 genes (37%)
were differentially regulated in AVH-B andCHBpatients
compared with HCs (see Supplementary Table 2).
Out of 118 genes, 100 genes were assigned to GO
terms using the Source annotation tool (Fig. 3A). The
majority of the genes were related to cellular processes
(24%), biological regulation (14%), response to stimulus
(13%), metabolic processes (12%), developmental pro-
cesses (11%), multicellular organismal processes (8%),
and immune system processes (7%). With respect to the
microarray-based analysis of the viral infection process,
we further dissected the GO term “response to stimulus”
(46 genes) (Fig. 3B) and “immune system process” (24
genes) (Fig. 3C).
Cluster Mapping and Affected Signaling Modules. The
cluster map was organized into six sections according to
the general expression behavior of the AVH-B and CHB
stage of infection as compared with HCs (Fig. 4). The
average relative gene expression values were calculated
from four (CHB patients and HCs) and three (AVH-B
patients) individual measures, respectively. Genes were
strictly down-regulated in AVH-B patients (cluster 1) or
in both AVH-B and CHB patients (cluster 2). Cluster 3
showed stronger expression in the AVH-B group com-
pared with the CHB group. Cluster 4 showed significant
reduction of expression of genes in the CHB group com-
pared with HC and AVH-B patients. In cluster 5, all
genes were specifically activated under acute but not
chronic conditions. Cluster 6 represents genes with strong
activation under both acute and chronic infection. All
genes displayed in the clustermapwere linked to signaling
maps stored in public databases by using MAPP Finder
software. T cell receptor (TCR) signaling, cell adhesion,
mitogen-activated protein kinase kinase (MAPKK) sig-
naling, cell cycle/cell proliferation, apoptosis, cytokines,
and chemokines were identified as the most prominently
affected modules (Fig. 5). Independently of any module,
Fig. 1. Frequency of (A) CD3CD4 and (B) CD4CD25Foxp3
T cells in peripheral blood of various subjects. Data are expressed as box
plots in which the horizontal lines indicate the 25th, 50th, and 75th
percentiles of the frequencies of the indicated T cells, as measured via
flow cytometry. The vertical lines represent the 10th and 90th percentiles.
The highest frequency of Tregs was observed in AVH-B patients (7%; HC
versus AVH-B, P  0.003; AVH-B versus CHB, P  0.04).
Fig. 2. Expression data obtained from the individual microarray mea-
sures were applied to principal components analysis. The use of this
statistical technique allowed us to determine the key variables in our
multidimensional dataset and visualize the observed variances within a
group (component 1 technical variances [y axis]) and between groups
(component 2  biological differences [x axis]), respectively. Abbrevia-
tions: HC, healthy control; CHB, chronic hepatitis B; AVH–B, acute
hepatitis B.
784 TREHANPATI, GEFFERS, ET AL. HEPATOLOGY, March 2009
the expression of NCF4 and MCM5, which are involved
in RNA and DNA replication, was up-regulated in both
acute and chronic hepatitis B.
Concerning the “TCR signaling and clusterization”
module, molecules such as CD4, CD3, VAV2, NCKAP,
SWAP70, and CISH were activated under acute infec-
tion. Under chronic conditions, the expression of these
molecules was suppressed, except for CD4 and CD3,
which were equally expressed in both stages. In the con-
text of the module cell adhesion and cell surface mole-
cules, overexpression of ICAM1 and PECAM1 in CD4
T cells was observed during AVH-B infection. On the
other hand, ERBB2, KSR, RABAC1, RASA3, and TIAM
are among the genes involved in MAPKK signaling that
were up-regulated in AVH-B. All these genes were down-
regulated during CHB infection. The expression of sev-
eral genes involved in the regulation of the cell cycle (such
as CDK4, CCND3, NEK2, PIM1, TGFB1, EGR1, and
EGR2) was much higher in AVH-B samples than in those
obtained from CHB patients and HCs.
During AVH-B infection, a variety of proteins in-
volved in apoptosis were up-regulated. Overexpression of
tumor necrosis factor (TNF), its ligands, and its receptors
(TNFSF5, TNFSF6, TNFRSF6, TNFRSF25, TN-
FRSF10, and TNFSF1) were observed during AVH-B
infection. Along with these genes, overexpression of the
perforin genes PRF1, LTA, BAX, and ATM, which are
proapoptotic, was observed during the acute stage. We
also observed different expression patterns for cytokines
influencing T cell activation and proliferation, as well as
the balance between TH1 and TH2 cells. Interleukin
(IL)-2RA, IL-7R, IL-7, IL-5, and interferon (IFN) signal-
regulating cytokines (such as IL-9, IL-4, IL1R2, IFNA1,
and SOCS2) were up-regulated in AVH-B infection. Mi-
croarray analysis also revealed higher expression of CCR4
and CCR8 in AVH-B patients than in CHB and HC.
Quantitative RT-PCR. Two representative up-regu-
lated genes, NCF4 and MCM5, were validated in an in-
dependent set of 14 AVH-B and 16 CHB patients and in
12 HCs via quantitative RT-PCR. An increased expres-
Fig. 3. Gene Ontology (GO) terms are used to identify the major functional classes of genes affected according to the signatures obtained from
AVH-B, CHB, and HC expression datasets. (A) Out of 118 differentially expressed genes, 100 genes can be mapped to GO terms allocating to
“Biological Process”. The most frequently affected GO terms were displayed as a pie diagram. The relative frequency by which a GO term is affected
through the expression signature is indicated for each section. Immunological relevant GO terms were shown as released pie sections and are further
analyzed. (B) 46 genes are linked to the GO term “Response to Stimulus” and (C) 24 genes are linked to the GO term “Immune System Process”.
The relative impact to the most affected GO terms is indicated, as described above.
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sion of NCF4 and MCM5 was observed in hepatitis pa-
tients compared with HCs (Fig. 6). There was no
significant difference between the expressions of NCF4 in
all patient categories. However, MCM5 expression was
higher in AVH-B patients than in CHB patients. These
RT-PCR results were in full agreement with the microar-
ray data (Supplementary Table 1), which also showed
up-regulation of CCR5 andCCR8.However, other com-
mon chemokine receptors, such as CCR1 and CCR3,
were not present on the customized chip. Therefore, we
expanded our studies by analyzing the CCR1, CCR3, and
CCR5 expression profiles via RT-PCR. An increased ex-
pression of CCR1, CCR3, and CCR5 was observed in
samples from AVH-B and CHB patients as compared
with HCs (Fig. 6). RT-PCR data also showed increased
expression ofNFKB in AVH-B andCHBpatients. This is
in functional agreement with the down-regulation of the
NFKBIA gene, an inhibitor of NFKB, which was de-
tected in the microarray studies.
Discussion
Differences in host immune response significantly af-
fect the outcome of HBV infection, Tregs being a major
player in the fine-tuning of T cell function. In contrast to
other studies,8,22 we found the highest number of Tregs in
AVH-B patients (7%), whereas the frequency was only
4% in CHB patients. Nevertheless, this value was still
two-fold higher than the percentage of Tregs in HCs
(2%) (Fig. 1B). It was described that during the convales-
cence phase of AVH-B infection, the number of Tregs
increases before the normal level is restored after resolu-
tion of the infection.22 This dynamic modulation of the
antiviral immune response via self-limited action of sup-
pressor Tregs might support the healing process at the site
of infection. The activity of Tregs might prevent the ex-
tended tissue damage resulting from an unchecked proin-
flammatory response. On the other hand, a
spatiotemporal dysregulation of Treg activity—that is,
uncontrolled establishment of suppressor activity at the
site of infection—could promote viral persistence and
progression to chronicity. This hypothesis is supported by
the increased number of circulating Tregs measured in
CHB patients as compared with HCs. The accumulation
of Tregs in the liver accompanied by viral persistence
illustrates the impact of Tregs on immune suppression.22
However, the molecular events are largely unknown.
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig. 4. Averaged expression signature of CD4 T cell pools isolated
from AVH-B and CHB patients as compared with HCs. One hundred
eighteen genes are shown passing ANOVA at a 95% confidence level
(internal controls were excluded) (Supplementary Table 2). Each lane
represents the average signal log intensity of three (AVH-B) and four
(CHB and HC) independent technical replicates. Multiple testing errors
were taken into consideration and corrected using the Benjamini-Hoch-
berg algorithm. Relative expression was displayed in red for increased
expression levels, green for decreased expression levels, and black for no
changed expression levels as compared with HCs. Color intensity was
calibrated to expression level as illustrated in the color legend at the
bottom of the cluster map. Cluster dissection is indicated on the
left-hand side; representative genes for each cluster are indicated on the
right-hand side.
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Microarray technology has a tremendous potential for
complementing classic biological and clinical parameters;
therefore, we used a human Treg chip16 to dissect specific
gene networks affected by the action of Tregs on CD4
T cells, which may contribute to the pathogenic stages of
acute and chronic HBV infection. To gain better insight
into this process, it would be necessary to study the gene
expression profiles of AVH-B adult patients who later
develop chronic infection. However, an extremely large
prospective patient cohort will be needed, because less
than 5%will develop chronic infection. To overcome this
bottleneck, we enrolled chronic HBV-infected adults
who are age- and sex-matched for the AVH-B patients.
Children were excluded, because they might be more im-
munotolerant.
Expression Signatures and Affected Signaling Mod-
ules. Expression of the NCF4 and MCM5 genes, which
are RNA andDNA replication genes, was up-regulated in
both AVH-B and CHB infection. Although not directly
attributable, NCF4 is known to favor the amplification of
viral RNA,23 whereas MCM5 is essential for the induc-
tion of STAT1 in response to IFN- stimulation and is
involved in DNA replication and transcription.24
Out of 118 genes, 100 genes were assigned to GO term
using the source annotation tool. Combining the results
from functional and expressional clusterization, we found
a large set of genes involved in immune response processes
activated under AVH-B infection, which were attenuated
or restored to normal levels during the chronic stage of
infection (Figs. 4 and 5). MAPP Finder software was used
for linking expression profiles to signaling maps stored in
public accessible databases20,21 and constructed the sig-
naling modules (Fig. 5). There is a considerable number
of genes acting not only in a particular module but also
Fig. 5. Signaling module depicting gene sets activated in CD4 T cells from AVH-B patients, which were attenuated or restored to normal levels
during the chronic stage of infection. Dotted lines represent a minor effect on gene expression or the specific process.
Fig. 6. Quantitative RT-PCR analysis of selected genes. MCM5, NCF4,
and CCR5 were used to confirm the results of microarray experiments.
The expression levels of CCR1, CCR3, and NF-B, which are known to
play an important role in infection processes, were also analyzed. Results
indicate relative expression levels as ratios of normalized mean gene
expression of infected patients as compared with HCs.
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cross-linking the individual modules. This highlights the
overall complexity of the underlying signaling modules.
TCR Signaling and Clusterization. Fully compe-
tent activation of T cells is mediated by the TCR, which
in turn facilitates the accumulation of TCR accessory
molecules, thereby forming a structure known as immu-
nological synapse. Molecules such as VAV2, NCKAP,
SWAP70, or CISH are part of this signaling complex or
are directly affected by this complex. Dysregulation or
mutation of these genes severely influences the outcome
of the immune response.25-29 We observed activation of
these components under acute infection, suggesting an
enhanced outside/inside signaling. Under chronic condi-
tions, the expression of these molecules was suppressed,
except for CD4 and CD3, thereby indicating an attenu-
ation of the signal transfer into the cell. The signal in-
duced upon activation of the TCR complex can be
transmitted to several other signaling modules, such as
activation ofMAPKK cascades, NF-B-mediated control
of cell proliferation, and activation of Ca2 release result-
ing in NFAT migration into the nucleus (Fig. 5).
Cell Adhesion and Cell Surface Molecules. Analysis
of the expression of cell adhesion and surface molecules
distinctly recognize the patterns of lymphocyte trafficking
in acute and chronic inflammations. ICAM1 and PE-
CAM1, which are overexpressed in the acute stage, have
shown their essential role for membrane trafficking and
transendothelial migration of activated leukocytes.30,31
MAPKK Signaling. ERBB2, KSR, RABAC1, RA-
SA3, and TIAM are among the genes involved in
MAPKK signaling that were up-regulated in AVH-B pa-
tients. These genes are part of the mitogen-activated pro-
tein kinase and are involved in the modulation and
stimulation by growth factors. Sequestration of the proto-
oncogene ERBB2 into an ERBB2 growth factor receptor
triggers the receptor complex to relay signals inside the
cell, thereby promoting cell growth, cellular survival, and
inflammation.32 A potential mechanism for ERBB2 acti-
vation of nuclear factor B (NF-B) is the phosphatidyl
inositol 3-kinase pathway, as documented in mammary
epithelial cells.33 However, the molecular mechanisms by
which all these molecules modulate the expression of cell
cycle genes and cell cycle progression warrant further in-
vestigation.
Cell Proliferation and Regulation of Cell Cycles.
The expression of several genes involved in the regulation
of the cell cycle, including CDK4, CCND3, NEK2,
PIM1, TGFB1, EGR1, EGR2, MCM5, and ATM, was
much higher in AVH-B samples than in those obtained
fromCHB patients andHCs. Regulation of cell cycle and
mitosis onset is mainly dependent on the activation of
cyclin-dependent kinases such as CDK4 and CCND3
(Fig. 5) and serine/threonine protein kinases such as
NEK2 and PIM1.34 Other molecules controlling prolif-
eration, differentiation, and mitogenesis are TGFB1,
EGR1, and EGR2.35-38
Apoptosis. Once the antigen is cleared, most of the T
cells die, and only a few are thought to remain as memory
cells. Activation-induced cell death is one of the main
mechanisms for T cell contraction in vivo. During
AVH-B infection, a variety of proteins involved in apo-
ptosis (such as TNFRSF25, TNFRSF10, TNFRSF5,
TNFRSF6, and TNFSF11) were up-regulated. TNF re-
ceptors are main components of the extrinsic pathway of
apoptosis, and NF-B activation and cellular apoptosis
are regulated through these receptors.39 Overexpression
of TNF and its receptors may stimulate the acute phase
reaction and play a role in regulating lymphocyte ho-
meostasis. Along with these genes, overexpression of the
perforin gene PRF1 has also been documented in TNF-
linked NF-B signaling and apoptosis.40,41 Other overex-
pressed genes in AVH-B includes LTA, BAX, and ATM,
which are proapoptotic, and have multiple functions in
cell-mediated cytolysis and apoptosis.42-44 The IGFBP4
gene, which is known for inducing NF-B-dependent
increased expression of BAX and BCL2 in apoptosis,45
was also overexpressed in the acute stage.
Cytokines and Chemokines. Different expression
patterns for cytokines influence T cell activation, as well as
the balance between TH1 and TH2 cells. IL2RA, IL-7,
IL-5, and IFN signaling regulating cytokines are up-reg-
ulated in AVH-B patients. IL2RA are the receptors that
bind and activate JAK proteins in the JAK-STAT path-
way. Previous studies have shown high levels of IL-2 and
IFN- in the acute phase of hepatitis.46 In response to
activation by a wide range of cytokines, SOCS proteins
are activated and become involved in the inhibition of the
IFN--dependent inflammatory response.47,48
On the other hand, chemokines are the driving force
for tissue-specific migration of inflammatory cells and T
cell recruitment. Disproportionate expression of chemo-
kine receptors in the affected organs provides the frame-
work for tissue-specific recruitment of helper and
cytotoxic T cell subsets. Moreover, up-regulation of
CCR1-expressing CD4T cells to the liver was observed
and treatment with a dual CCR1/CCR5 peptide antago-
nist, methionylated RANTES, was used to reduce hepatic
injury and decrease the numbers of CD4 T cells pro-
ducing IFN- within the liver.49 Up-regulation of CCR5
and other chemokines also suggests that T cells may
respond to increases in virus replication by efficiently
migrating into the infected liver.50 Up-regulation of
CCR5, CCR4, and CCR8 is also known for macro-
phage recruitment, activation, and differentiation of
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Treg and TH2 effector lymphocytes.51 We found
higher expression of CCR4 and CCR8 in AVH-B pa-
tients, which also showed higher frequencies of Tregs
in the periphery.
It could be argued that a study comparing patients who
develop CHB infection in adulthood with those who de-
velop AVH-B infection in adulthood would help exclude
a possible overlay of patients whose infectionwas acquired
during childhood but not detected until adulthood.
However, the likelihood of the former group of patients is
rather low; only about 1% of AVH-B infections acquired
during adulthood are likely to become chronic, so approx-
imately 1,000 AVH-B–infected patients would need to be
followed to find 10 well-characterized CHB patients. The
selection of healthy adult donors with high anti-HBs ti-
ters and negative total anti-HBc status, as done in the
present study, allows a good comparison between acute
HBV infections in adulthood with healthy controls.
To the best of our knowledge, differential expression of
these genes has not been previously reported to be associ-
ated with the pathogenic mechanisms operating during
the different stages of HBV infection. The observed up-
regulation of activation markers, chemokines, inflamma-
tory response genes, and apoptotic genes in the circulating
CD4T cells provides the conceptual framework to sup-
port the necro-inflammation observed at the target organ
as a result of effector cell accumulation, active prolifera-
tion, apoptosis, and cellular lysis in AVH-B patients. On
the other hand, the clear down-regulation of these genes
during the chronic stage supports the hypothesis of sup-
pressed CD4 effector response favoring viral persis-
tence. The information generated in this study suggests
that the in-depth investigation of the changes in major
gene programs during the follow-up of AVH-B and CHB
patients would allow us to elucidate the molecular path-
ways underlying the decision-making processes.
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